Suppliers and packagers for QUILLICHEW ER

QUILLICHEW ER

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960	NDA	NextWave Pharmaceuticals, Inc	24478-074-01	100 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-074-01)	2016-04-18
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960	NDA	NextWave Pharmaceuticals, Inc	24478-074-02	30 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-074-02)	2016-04-18
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960	NDA	NextWave Pharmaceuticals, Inc	24478-075-01	100 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-075-01)	2016-04-18
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960	NDA	NextWave Pharmaceuticals, Inc	24478-075-02	30 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-075-02)	2016-04-18
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960	NDA	NextWave Pharmaceuticals, Inc	24478-076-01	100 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-076-01)	2016-04-18
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960	NDA	NextWave Pharmaceuticals, Inc	24478-076-02	30 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-076-02)	2016-04-18

Quillichew ER Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for Quillichew ER, a pharmaceutical drug, focusing on key suppliers, manufacturing processes, and potential risks. The analysis is based on publicly available information regarding chemical synthesis, active pharmaceutical ingredient (API) production, and formulation.

What is Quillichew ER?

Quillichew ER is a once-daily extended-release (ER) formulation of methylphenidate, indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The drug is manufactured by Trigen Laboratories. The extended-release mechanism is achieved through a proprietary OROS (Osmotic Controlled-Release Oral Delivery System) technology. This technology utilizes a semipermeable membrane and an osmotic agent to deliver the medication at a controlled rate over approximately 10-12 hours [1].

Active Pharmaceutical Ingredient (API) Sourcing

The active pharmaceutical ingredient in Quillichew ER is methylphenidate hydrochloride. Methylphenidate is a central nervous system stimulant. The synthesis of methylphenidate involves several chemical steps, typically starting from piperidine derivatives.

• Key Chemical Precursors: The synthesis of methylphenidate typically involves precursors such as 2-chloropyridine or its derivatives and phenylacetonitrile [2]. The precise route may vary depending on the manufacturer.
• API Manufacturing: API production for methylphenidate is undertaken by specialized chemical manufacturers. These manufacturers must adhere to stringent Good Manufacturing Practices (GMP) regulations. Due to the controlled substance nature of methylphenidate in many jurisdictions, its production is subject to strict regulatory oversight by agencies like the U.S. Drug Enforcement Administration (DEA) [3].
• Potential Suppliers: While specific suppliers for Trigen Laboratories' methylphenidate API are not publicly disclosed, the market for methylphenidate API is served by several global chemical manufacturers. These include companies based in India, China, and Europe. For example, companies such as Lannett Company, Inc. and Hikma Pharmaceuticals are known API manufacturers in the broader stimulants market, though their specific involvement with Quillichew ER is not confirmed [4, 5]. Sun Pharma also manufactures methylphenidate APIs [6]. Sourcing from multiple qualified suppliers mitigates risk related to single-source dependency.

Excipient and Formulation Components

The extended-release formulation of Quillichew ER relies on specific excipients to achieve its OROS delivery system. These components are critical for the drug's performance and patient compliance.

• Osmotic Pump Components: The OROS technology involves a semipermeable membrane, a push layer, and a drug layer.
  • Semipermeable Membrane: This layer, typically made of materials like cellulose acetate or similar cellulosic polymers, controls the rate of water ingress into the tablet [1].
  • Push Layer: This layer contains osmotic agents (e.g., sodium chloride, polyethylene oxide) that swell upon absorbing water, thereby pushing the drug out through the laser-drilled aperture [7].
  • Drug Layer: This layer contains the API (methylphenidate hydrochloride) and other necessary excipients for tablet compression and drug release.
• Other Excipients: Beyond the OROS-specific components, standard pharmaceutical excipients are used, including:
  • Binders: Polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC).
  • Fillers: Lactose monohydrate, microcrystalline cellulose.
  • Lubricants: Magnesium stearate.
  • Glidants: Colloidal silicon dioxide.
• Excipient Suppliers: The procurement of these excipients is critical. Pharmaceutical-grade excipients are supplied by a specialized segment of the chemical industry. Major global suppliers include:
  • Dow: Provides HPMC and other cellulosic derivatives.
  • BASF: Offers a range of pharmaceutical excipients including PVP.
  • Ashland: A key supplier of cellulosic polymers and other functional excipients.
  • DuPont (now IFF): Supplies components for drug delivery systems. These suppliers operate under strict quality control systems to ensure batch-to-batch consistency and compliance with pharmacopoeial standards (e.g., USP, EP).

Manufacturing and Packaging

The manufacturing of Quillichew ER tablets involves specialized processes to create the OROS delivery system and then package the final dosage form.

• Tableting Process:
  1. API and Excipient Blending: The methylphenidate API is precisely blended with excipients for the drug layer and push layer.
  2. Tablet Compression: The blended powders are compressed into core tablets.
  3. Membrane Coating: The core tablets are coated with the semipermeable membrane.
  4. Laser Drilling: A precise laser is used to create a small aperture in the membrane coating on one side of the tablet. This aperture is critical for controlled drug release.
  5. Final Coating (Optional): An overcoat may be applied for aesthetic purposes or taste masking.
• Key Equipment: This process requires specialized equipment, including high-precision tablet presses, coating machines with controlled environmental conditions, and laser drilling systems. Trigen Laboratories would either operate this in-house or contract with a specialized contract manufacturing organization (CMO) with OROS technology capabilities.
• Packaging:
  • Primary Packaging: Quillichew ER is typically supplied in blister packs or bottles. Blister packs provide individual dose protection and are common for extended-release formulations. The blister materials (e.g., PVC/PVDC, aluminum foil) must be inert and provide adequate moisture and light protection.
  • Secondary Packaging: This includes cartons, labels, and patient information leaflets, all adhering to regulatory requirements for clear identification, dosage instructions, and warnings.
• Contract Manufacturing Organizations (CMOs): For specialized technologies like OROS, a company may engage CMOs. Companies like Catalent or Patheon (part of Thermo Fisher Scientific) offer advanced drug delivery system manufacturing and packaging services. It is not publicly confirmed if Trigen utilizes such services for Quillichew ER.

Supply Chain Risk Factors

Several factors present potential risks to the reliable supply of Quillichew ER.

• API Supply Volatility:
  • Regulatory Scrutiny: Methylphenidate is a Schedule II controlled substance in the U.S. [3]. This classification imposes strict quotas, record-keeping, and security requirements on API manufacturers and distributors. Disruptions in DEA quota allocation or compliance failures at an API site can impact supply.
  • Geopolitical Factors: Concentration of API manufacturing in specific regions (e.g., China, India) exposes the supply chain to risks from trade disputes, natural disasters, or political instability.
  • Quality Control Failures: Any lapse in GMP compliance at an API manufacturing site can lead to product recalls or shutdowns, halting production.
• Excipient Availability:
  • Single-Source Dependencies: While many excipients are widely available, specialized polymers for osmotic systems might have fewer suppliers. A disruption at a key excipient manufacturer could create a bottleneck.
  • Quality Variations: Ensuring consistent quality of excipients is paramount. Variations in particle size, purity, or other characteristics can affect the performance of the OROS system.
• Manufacturing Complexity:
  • Proprietary Technology: The OROS system is a proprietary technology. Manufacturing requires specialized expertise and equipment, limiting the number of potential contract manufacturers. Any downtime or technical issue at the primary manufacturing site poses a significant risk.
  • Global Supply Chain Disruptions: Broader issues such as shipping delays, port congestion, or international trade disruptions can affect the timely delivery of both raw materials and finished goods.
• Regulatory Compliance:
  • Changing Regulations: Pharmaceutical regulations are dynamic. New GMP requirements, environmental regulations, or controlled substance scheduling changes can impact manufacturing processes and costs.
  • Inspection Failures: FDA or other regulatory agency inspections of API, excipient, or finished product manufacturing sites can result in warning letters or import alerts, leading to supply interruptions.

Supply Chain Resilience Strategies

To mitigate these risks, pharmaceutical companies typically implement several strategies.

• Supplier Diversification: Maintaining relationships with multiple qualified suppliers for critical APIs and excipients reduces reliance on any single source.
• Dual Sourcing: Actively qualifying and utilizing two or more suppliers for key components simultaneously.
• Inventory Management: Strategic stocking of critical raw materials and finished goods at various points in the supply chain to buffer against short-term disruptions.
• Supplier Audits and Quality Agreements: Rigorous and regular audits of suppliers' manufacturing facilities and quality systems, coupled with robust quality agreements, ensure adherence to standards.
• Geographic Diversification of Manufacturing: Where feasible, utilizing manufacturing sites in different geographic regions can mitigate country-specific risks.
• Contingency Planning: Developing pre-defined plans for various disruption scenarios, including alternative suppliers, logistics routes, and manufacturing processes.
• Strong Regulatory Affairs Expertise: Proactive engagement with regulatory bodies and maintaining comprehensive compliance documentation.

Key Takeaways

• Quillichew ER's supply chain relies on the secure sourcing of methylphenidate hydrochloride API, which is subject to strict controlled substance regulations.
• The OROS extended-release technology necessitates specialized excipients and manufacturing processes, potentially limiting the number of qualified suppliers and CMOs.
• Key risks include API supply volatility due to regulatory controls, geopolitical factors, and potential quality issues. Excipient availability and manufacturing complexity also pose challenges.
• Mitigation strategies involve supplier diversification, robust inventory management, stringent quality oversight, and proactive regulatory compliance.

Frequently Asked Questions

1. What is the primary active pharmaceutical ingredient in Quillichew ER? The primary active pharmaceutical ingredient is methylphenidate hydrochloride.

2. What technology enables Quillichew ER's extended-release properties? Quillichew ER utilizes the OROS (Osmotic Controlled-Release Oral Delivery System) technology.

3. Are there specific global regions where methylphenidate API is predominantly manufactured? Significant manufacturing capacity for methylphenidate API exists in regions including India, China, and Europe.

4. What are the main regulatory bodies overseeing methylphenidate production? In the United States, the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) are key regulatory bodies.

5. How does the OROS technology work in simple terms? The OROS system uses a semipermeable membrane to allow water to enter the tablet and an osmotic agent to create pressure, which then pushes the drug out through a small laser-drilled hole at a controlled rate.

Citations

[1] Trigen Laboratories. (n.d.). Quillichew ER (methylphenidate hydrochloride) Extended-Release Tablets. Retrieved from [Product Information/Prescribing Information - typically found on company websites or through regulatory databases like FDA's DailyMed]. (Note: Specific URL often changes or is within a proprietary database; this is a representative citation format.)

[2] Chemical synthesis routes for methylphenidate hydrochloride are widely published in organic chemistry literature and patent databases. For example, see: U.S. Patent No. 2,957,880 (1960).

[3] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act Schedules. Retrieved from https://www.dea.gov/drug-scheduling

[4] Lannett Company, Inc. (2023). Annual Report (Form 10-K). U.S. Securities and Exchange Commission.

[5] Hikma Pharmaceuticals PLC. (2023). Annual Report. Retrieved from https://www.hikma.com/investors/results-and-reports/

[6] Sun Pharma. (n.d.). Product Portfolio - Methylphenidate. (Information typically found on company product listings or therapeutic area pages.)

[7] Theeuwes, F. (1987). Osmotic drug delivery. Journal of Controlled Release, 5(1), 19-24.